This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Journal of Experimental & Clinical Cancer Research Open Access 05 January 2023
-
The Gibco™ CTS™ Rotea™ system story—a case study of industry-academia collaboration
Gene Therapy Open Access 10 June 2021
-
Nanoparticle-Loaded Polarized-Macrophages for Enhanced Tumor Targeting and Cell-Chemotherapy
Nano-Micro Letters Open Access 27 October 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L.P. and A.S. are not employees but consultants to Cancer Research Institute. All other authors declare no competing interests.
Related links
Supplementary information
Supplementary Figure 1
Numbers of different types of cell therapies in development. (PDF 110 kb)
Supplementary Figure 2
The number of different types of cell therapies in development per country. (PDF 154 kb)
Supplementary Figure 3
The contribution of academic institutes to cancer cell therapy development. (PDF 122 kb)
Supplementary Table
The list of trials that combine cell therapies with anti-PD1/L1 agents. (PDF 76 kb)
Rights and permissions
About this article
Cite this article
Tang, J., Hubbard-Lucey, V., Pearce, L. et al. The global landscape of cancer cell therapy. Nat Rev Drug Discov 17, 465–466 (2018). https://doi.org/10.1038/nrd.2018.74
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.74
This article is cited by
-
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Journal of Experimental & Clinical Cancer Research (2023)
-
The Gibco™ CTS™ Rotea™ system story—a case study of industry-academia collaboration
Gene Therapy (2023)
-
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
Nature Biotechnology (2022)
-
Advancing T cell–based cancer therapy with single-cell technologies
Nature Medicine (2022)
-
Nanoparticle-Loaded Polarized-Macrophages for Enhanced Tumor Targeting and Cell-Chemotherapy
Nano-Micro Letters (2021)